A retrospective analysis of outpatient use of small-molecule targeted inhibitors for lymphoma across six regions of China (2016–2022)

Between 2016 and 2022, the prescription volume of small-molecule targeted inhibitors for lymphoma increased annually, indicating their expanding clinical use. Since 2020, despite continued growth in prescriptions, drug costs have risen at a slower rate than prescriptions. This reflects that medical insurance negotiation and centralized procurement policies have effectively reduced economic burden without limiting their access to these inhibitors. Pharmacoeconomic indicators also confirm that the use of these drugs has been both reasonable and efficient, allowing for increased drug utilization while reducing financial strain.